This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sandoz, Novartis must face US antitrust claims over generic drugs, states argue

( April 25, 2025, 22:31 GMT | Official Statement) -- MLex Summary: US state attorneys general opposed Novartis AG and Sandoz AG’s motions to dismiss antitrust claims over an alleged generic drug price-fixing conspiracy, saying they cannot claim to be strangers to the US. “The [second amended complaint] details how defendants operated a unified global enterprise for years, directing and controlling Sandoz’s anticompetitive activities while helping to conceal its illegal activities and transferring its cash overseas,” they argued. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections